[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578529":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":27,"locations":36,"responsibleParty":52,"collaborators":10,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":10,"enrollmentInfo":64,"targetDuration":67,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":74,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Balikesir University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"group 1",null,"ACB risk score of 3 or more (high risk).",[13],"Other: Anticholinergic load was calculated using anticholinergic cognitive load (ACB)",{"label":15,"type":10,"description":16,"interventionNames":17},"group 2","ACB risk score of less than 3 (low risk)",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"Anticholinergic load was calculated using anticholinergic cognitive load (ACB)","Bone mineral density was measured using a Dual Energy X-ray Absorptiometry (DEXA) device.\n\nFracture Risk Assessed with Fracture Risk Assessment Tool (FRAX).",[9,15],[24],{"name":25,"affiliation":5,"role":26},"Bilal UYSAL, assistant prof.","PRINCIPAL_INVESTIGATOR",[28,34],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Bilal UYSAL, assistant professor","CONTACT","2666121010","4450","bilaluysal@gmail.com",{"name":35,"role":30,"phone":31,"phoneExt":32,"email":10},"Ender SALBAS, assistant professor",[37],{"facility":38,"status":39,"city":40,"state":10,"zip":41,"country":42,"countryCode":10,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Balikesir University Health Practice and Research Hospital","RECRUITING","Balıkesir","10145","Turkey (Türkiye)",{"type":44,"coordinates":45},"Point",[46,47],27.88611,39.64917,{"lat":47,"lon":46},[50],{"name":29,"role":30,"phone":51,"phoneExt":32,"email":33},"+902666121010",{"type":26,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Bilal Uysal","Assistant professor","100578529","anticholinergic-burden-and-osteoporosis-in-rheumatoid-arthritis-100578529",false,"NCT06812481","Anticholinergic Burden and Osteoporosis in Rheumatoid Arthritis","Anticholinergic Drug Use in Patients With Rheumatoid Arthritis and Its Effects on Fracture Risk","Inclusion Criteria:\n\n* Patients diagnosed with rheumatoid arthritis\n\nExclusion Criteria:\n\n* Kemik metabolizmasını etkileyen sistemik hastalıkları veya ilaçları kullanan hastalar,\n* Kemik mineral yoğunluk ölçümünü etkileyen kalça veya lomber vertebralarda metalik materyalleri olan hastalar","ALL","18 Years",{"count":65,"type":66},100,"ESTIMATED","3 Months","OBSERVATIONAL","Background: Rheumatoid arthritis (RA) is a chronic, progressive, inflammatory rheumatological disease. Use of corticosteroids for more than 3 months in RA treatment is considered an important risk factor in terms of developing secondary osteoporosis and increasing the risk of fracture. The cumulative effect of taking one or more drugs with anticholinergic properties is called anticholinergic load. It is stated that anticholinergic load also increases the risk of fracture in individuals. The aim of this study is to investigate the effects of drugs used by patients with Rheumatoid Arthritis (RA) on anticholinergic load and fracture risk. The Fracture Risk Assessment Tool (FRAX) will be used to assess fracture risk in patients.\n\nMaterials and methods: The study was planned as a prospective cohort study. The study will included 100 patients who were followed up as outpatients with rheumatoid arthritis diagnosis in the physical medicine and rehabilitation clinic between 2024-2025. Patients of both genders and over 18 years of age diagnosed with rheumatoid arthritis will be included in the study. Patients with systemic diseases or medications affecting bone metabolism and those with metallic materials in the hip or lumbar vertebrae affecting bone mineral density measurement will be excluded from the study. Demographic characteristics, systemic diseases, medications used, bone density measurement and blood test values of the patients will be recorded.\n\nPatients taking multiple medications with anticholinergic effects create an anticholinergic burden. The Anticholinergic Drug Scale, Anticholinergic Cognitive Burden Scale and Anticholinergic Risk Scale will be used to measure anticholinergic burden in the study.",[71,72,73],"Rheumatoid Arthritis (RA)","Anticholinergic Adverse Reaction","Fractures, Bone",[75,76,77],"Rheumatoid arthritis","anticholinergic load","risk of fracture","2025-09-16",{"date":80,"type":81},"2025-09-18","ACTUAL",{"date":83,"type":81},"2025-09-15",{"date":85,"type":66},"2025-12-31",{"name":5,"class":6},1]